Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes

OBJECTIVE To assess the relative impact of an intensive lifestyle intervention (ILI) on use and costs of health care within the Look AHEAD trial. RESEARCH DESIGN AND METHODS A total of 5,121 overweight or obese adults with type 2 diabetes were randomly assigned to an ILI that promoted weight loss or to a comparison condition of diabetes support and education (DSE). Use and costs of health-care services were recorded across an average of 10 years. RESULTS ILI led to reductions in annual hospitalizations (11%, P = 0.004), hospital days (15%, P = 0.01), and number of medications (6%, P < 0.001), resulting in cost savings for hospitalization (10%, P = 0.04) and medication (7%, P < 0.001). ILI produced a mean relative per-person 10-year cost savings of $5,280 (95% CI 3,385–7,175); however, these were not evident among individuals with a history of cardiovascular disease. CONCLUSIONS Compared with DSE over 10 years, ILI participants had fewer hospitalizations, fewer medications, and lower health-care costs.

[1]  Lawrence J Appel,et al.  Prevalence of obesity in the United States. , 2014, JAMA.

[2]  Jennette P. Moreno,et al.  Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.

[3]  T. Wadden,et al.  Cost-effectiveness of a primary care intervention to treat obesity , 2013, International Journal of Obesity.

[4]  Morton B. Brown,et al.  The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS , 2013 .

[5]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[6]  Haiying Chen,et al.  Association of an intensive lifestyle intervention with remission of type 2 diabetes. , 2012, JAMA.

[7]  Edward H Ip,et al.  Lifestyle change and mobility in obese adults with type 2 diabetes. , 2012, The New England journal of medicine.

[8]  Ping Zhang,et al.  The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention , 2012, Diabetes Care.

[9]  S. Wolfenstetter.  Future direct and indirect costs of obesity and the influence of gaining weight: results from the MONICA/KORA cohort studies, 1995-2005. , 2012, Economics and human biology.

[10]  Katherine M Flegal,et al.  Prevalence of obesity in the United States, 2009-2010. , 2012, NCHS data brief.

[11]  W. Davis,et al.  Economic impact of moderate weight loss in patients with Type 2 diabetes: The Fremantle Diabetes Study , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[12]  J. Harvey-Berino,et al.  Comparing Behavioral Weight Loss Modalities: Incremental Cost‐Effectiveness of an Internet‐Based Versus an In‐Person Condition , 2011, Obesity.

[13]  Jacqueline Wesche-Thobaben.  The development and description of the comparison group in the Look AHEAD trial , 2011, Clinical trials.

[14]  H. Glick,et al.  Direct medical cost of overweight and obesity in the USA: a quantitative systematic review , 2011, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[15]  Rena R Wing,et al.  Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. , 2010, Archives of internal medicine.

[16]  T. Wadden,et al.  Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes , 2010, Diabetologia.

[17]  Brenda Montgomery,et al.  Effect of the Look AHEAD Study Intervention on Medication Use and Related Cost to Treat Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2010, Diabetes Care.

[18]  Michael O'Grady,et al.  Projecting the Future Diabetes Population Size and Related Costs for the U.S. , 2009, Diabetes Care.

[19]  T. Wadden,et al.  A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. , 2009, Archives of internal medicine.

[20]  E. Finkelstein,et al.  Annual medical spending attributable to obesity: payer-and service-specific estimates. , 2009, Health affairs.

[21]  Mark A Pereira,et al.  Effect of a Lifestyle Intervention on Change in Cardiorespiratory Fitness in Adults with Type 2 Diabetes: Results from the Look AHEAD Study , 2008, International Journal of Obesity.

[22]  M. Happich,et al.  Direct costs and health-related resource utilisation in the 6 months after insulin initiation in German patients with type 2 diabetes mellitus in 2006: INSTIGATE study* , 2008, Current medical research and opinion.

[23]  J. Leahy.  Economic Costs of Diabetes in the U.S. in 2007 , 2008 .

[24]  M. Conaway,et al.  Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). , 2007, Journal of the American Dietetic Association.

[25]  H. Hauner,et al.  The cost burden of diabetes mellitus: the evidence from Germany—the CoDiM Study , 2006, Diabetologia.

[26]  T. Wadden,et al.  The Look AHEAD Study: A Description of the Lifestyle Intervention and the Evidence Supporting It , 2006, Obesity.

[27]  D. Shera,et al.  Cost-effectiveness of a low-carbohydrate diet and a standard diet in severe obesity. , 2005, Obesity research.

[28]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[29]  C. Still,et al.  Bariatric Surgery: Shedding the Monetary Weight of Prescription Costs in the Managed Care Arena , 2004, Obesity surgery.

[30]  Karen C Johnson,et al.  Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. , 2003, Controlled clinical trials.

[31]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[32]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[33]  J. Rood,et al.  Pharmaceutical cost savings of treating obesity with weight loss medications. , 1999, Obesity research.

[34]  R. Collins,et al.  Medication cost savings associated with weight loss for obese non-insulin-dependent diabetic men and women. , 1995, Preventive medicine.

[35]  R. Little.  Pattern-Mixture Models for Multivariate Incomplete Data , 1993 .

[36]  R. Little.  Regression with Missing X's: A Review , 2011 .